0 3 2004

## INFORMATION DISCLOSURE STATEMENT

Moon K. Song

App. No.

10/768,200

Filed

January 30, 2004

For

**COMPOSITIONS AND METHODS** 

FOR TREATING OBESITY

Examiner

Unknown

Group Art Unit

1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, PO Box 1450, Alexandria, VA 22313-1450, on

29 July 28, 2004

(Date)

Daniel E. Altman, Reg. No. 34,115

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 12 references. Copies of disclosed U.S. patents and/or publications are not included pursuant to PTO waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i) for applications filed after June 30, 2003. Copies of other references, if listed, are enclosed.

Identification herein is not an admission that any of the foregoing are prior art to the above captioned application.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

By:

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 29 July 2004

Daniel E. Altman

Registration No. 34,115

Attorney of Record

Customer No. 20,995

(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. MOONSO.003A

APPLICATION NO. 10/768,200

AUG 0 3 2004

MADRMATION DISCLOSURE STATEMENT
BY APPLICANT

SEVERAL SHEETS IF NECESSARY)

APPLICANT Moon K. Song

FILING DATE January 30, 2004 GROUP 1614

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	5,411,748	05/1995	Song			
	2.	5,418,218	05/1995	Wilber			
	3.	5,834,032	11/1998	Song			
	4.	5,989,574	11/1999	Slavin			
	5.	5,997,908	12/1999	Song			

FOREIGN PATENT DOCUMENTS								
EXAMINER		DOCUMENT NUMBER	DATE ·	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
INITIAL						·	YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					
	6.	Effects of arachidonic acid plus zinc on glucose disposal in genetically diabetic (ob/ob) mice, I.K. Hwang et al., Diabetes, Obesity and Metabolism, 4 2002, pp. 124-131				
	7.	Antidiabetic Actions of Arachidonic Acid and Zinc in Genetically Diabetic Goto-Kakizaki Rats, Moon K. Song et al., Metabolism, Vol. 52, No. 1 (January), 2003; pp. 7-12				
	8.	Synergistic Antidiabetic Activities of Zinc, Cyclo (His-Pro), and Arachidonic Acid, Moon K. Song et al., Metabolism, Vol. 50, No. 1 (January), 2001; pp. 53-59				
	9.	Animal Prostate Extract Ameliorates Diabetic Symptoms by Stimulating Intestinal Zinc Absorption in Rats, M.K. Song et al., Diabetes Research (1996), 31: pp. 157-170				
•	10.	Metabolism of Glucose by Rat Pancreatic Islets and Kidney: Comparison of Membrane Preparations with Intact Tissue, Moon K. Song et al., Pancreas, Vol. 24, No. 2, 2002, pp. 205-209				
	11.	Effects of Bovine Prostate Powder on Zinc, Glucose, and Insulin Metabolism in Old Patients with Non-Insulin- Dependent Diabetes Mellitus, M.K. Song et al., Metabolism, Vol. 47, No. 1 (January), 1998, pp. 39-43				
	12.	Effects of arachidonic acid and cyclo (his-pro) on zinc transport across small intestine and muscle tissues; M.J. Rosenthal et al., Life Sciences 70 (2001) 337-348				

EXA	MIN	IER

DATE CONSIDERED

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.